![]() |
|
|
Seattle Biomedical Research Institute
To examine the possibility for drug metabolism polymorphism, adult
human flavin-containing monooxygenases (form 3) (EC 1.14.13.8) that
differ at one amino acid were expressed in Escherichia coli as maltose binding protein fusions. The cDNA that was first reported during the cloning of adult human flavin-containing monooxygenase was
designated the wild type lys158 enzyme. A
second cDNA has been identified as a common polymorphism in some human
populations and was designated the glu158
enzyme. The cDNA that encodes both enzymes was subcloned into a high
yield protein fusion expression system, expressed, and the protein was
partially purified by affinity chromatography and characterized for
enzyme activity with selective functional substrate probes.
N- and S-oxygenation activity of both enzymes was determined with
10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine and
methyl p-tolyl sulfide, respectively. It was found that
expression of both lys158 and
glu158 enzymes of the human flavin-containing
monooxygenase form 3 as fusions with the maltose binding protein
resulted in an enzyme that was soluble and greatly stabilized and had a
reduced requirement for detergent during enzyme purification and during
the assay for activity. Expression of the fusion proteins has allowed
the preparation of stable and highly active enzyme at greater purity than was readily possible in the past. With the exception of the stability and solubility characteristics, the physical and chemical properties of lys158 and
glu158 maltose binding fusion proteins of human
flavin-containing monooxygenase form 3 variants resembled that of
flavin-containing monooxygenase enzyme activity associated with human
liver microsomes and enzyme isolated from a previous Escherichia
coli expression system that lacked the protein fusion. Comparison
of the catalytic activity of the two fusion proteins showed that while
both forms were active, there were differences in their substrate
specificities. Expression of the adult human flavin-containing
monooxygenase form 3 as a maltose binding protein has allowed
considerable advances over the previously reported cDNA-expressed
enzyme systems and may provide the basis for examining the role of the
flavin-containing monooxygenase in human xenobiotic or drug metabolism.
This article has been cited by other articles:
![]() |
T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3 Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lattard, J. Zhang, and J. R. Cashman Alternative Processing Events in Human FMO Genes Mol. Pharmacol., June 1, 2004; 65(6): 1517 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cashman, V. Lattard, and J. Lin EFFECT OF TOTAL PARENTERAL NUTRITION AND CHOLINE ON HEPATIC FLAVIN-CONTAINING AND CYTOCHROME P-450 MONOOXYGENASE ACTIVITY IN RATS Drug Metab. Dispos., February 1, 2004; 32(2): 222 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lattard, J. Zhang, Q. Tran, B. Furnes, D. Schlenk, and J. R. Cashman TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES Drug Metab. Dispos., July 1, 2003; 31(7): 854 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhao, S. K. Christensen, C. Fankhauser, J. R. Cashman, J. D. Cohen, D. Weigel, and J. Chory A Role for Flavin Monooxygenase-Like Enzymes in Auxin Biosynthesis Science, January 12, 2001; 291(5502): 306 - 309. [Abstract] [Full Text] |
||||
![]() |
J. R. Cashman, B. R. Akerman, S. M. Forrest, and E. P. Treacy Population-Specific Polymorphisms of the Human FMO3 Gene: Significance for Detoxication Drug Metab. Dispos., February 1, 2000; 28(2): 169 - 173. [Abstract] [Full Text] |
||||
![]() |
J. R. Cashman, Y. N. Xiong, L. Xu, and A. Janowsky N-Oxygenation of Amphetamine and Methamphetamine by the Human Flavin-Containing Monooxygenase (Form 3): Role in Bioactivation and Detoxication J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1251 - 1260. [Abstract] [Full Text] |
||||